立即登录 | 免费注册
全部学科 | 内科学 | 心血管病学 | 内分泌学与糖尿病 | 神经病学 | 消化病学 | 呼吸病学 | 肿瘤学 | 妇产科学 | 骨科学
疾病中心： 高血压 | 冠心病 | 心力衰竭 | 心律失常 | 脂肪性肝病 | 糖尿病 | 卒中 | 慢性阻塞性肺病 | 子宫内膜异位症 | 乳腺癌 | 肺癌 | 结直肠癌 | 器官移植
Loading
当前位置：期刊中心 > 全球精选文摘 > 文摘导读

在帕金森病中使用多巴胺激动剂对左旋多巴药物效应动力学的影响

Effects of a Dopamine Agonist on the Pharmacodynamics of Levodopa in Parkinson Disease
Brodsky MA, Park BS, Nutt JG   |    2010/4/21 16:31:23   | 
Arch Neurol  |   2010   |          View at Publisher
专家评级： ★★  |    循证评级： A   |  【全球专家评论】 |   打印| 推荐给好友
上一篇： 利妥昔单抗对合并IgM单克隆球蛋白病的多发性神经病的疗效
下一篇： 有胃轻瘫症状的糖尿病患者放射性核素胃排空检查示延迟预示着并发症的发生
Background:
Treatment of Parkinson disease commonly includes levodopa and dopamine agonists; however, the interaction of these 2 drugs is poorly understood.

Objective:
To examine the effects of a dopamine agonist on the motor response to levodopa.

Design:
Double-blind, randomized, placebo-controlled, crossover clinical trial.

Setting:
Ambulatory academic referral center.

Patients:
Thirteen patients with idiopathic Parkinson disease taking levodopa and experiencing motor fluctuations and dyskinesia.

Interventions:
Eligible individuals were randomly assigned to receive pramipexole dihydrochloride or placebo for 4 weeks followed by a 2-hour intravenous levodopa infusion on consecutive days at 2 rates and with blinded assessments. They were then crossed over to the alternate oral therapy for 4 weeks followed by levodopa infusion and reassessment.

Main Outcome Measures:
Change in finger-tapping speed, measured using the area under the curve (AUC) for finger taps per minute across time; peak fingertapping speed; duration of response; time to “ON” (defined as a 10% increase in finger-tapping speed above baseline); walking speed; and dyskinesia AUC.

Results:
Pramipexole with levodopa infusion increased finger-tapping speed beyond the change in baseline by a mean (SE) of 170 (47.2) per minute×minutes (P=.006) and more than doubled the AUC for finger-tapping speed. Pramipexole increased peak finger-tapping speed by a mean (SE) of 18 (8.5) taps per minute (P=.02) and improved mean (SE) walking speed (15.9 [0.70] vs 18.9 [0.70] seconds, P=.004). Pramipexole prolonged duration of response after levodopa infusion and shortened time to ON. Pramipexole increased mean (SE) baseline dyskinesia scores (26.0 [5.85] vs 12.1 [5.85] points, P=.05) and peak dyskinesia scores with levodopa infusion.

Conclusions:
Pramipexole augmented the motor response to levodopa beyond a simple additive effect and increased the severity of levodopa-induced dyskinesia. When considering a combination of these therapies, an appropriate balance should be maintained regarding gain of motor function vs worsening of dyskinesia.

Trial Registration:
clinicaltrials.gov Identifier: NCT00666653
关键词:

请登录后发表评论，点击此处登录。

慢性心衰诊治：规范中求突破
黄峻
2012-2-1
南京医科大学第一附属医院
房颤治疗：手段渐趋丰富 新型治疗药物不断涌现 非药物治疗备受关注
马长生
2012-2-1
首都医科大学附属北京安贞医院
注重老年人群特征 优化管理

刘梅林
2012-2-1
北京大学第一医院老年内科

 
相关文章